NucleoTech

Company Overview

Snapshot

Founded in January 2023, NucleoTech operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing advanced drug delivery solutions.

Business overview

NucleoTech is a Health Tech & Life Sciences company focused on overcoming the limitations of drug delivery to the brain, particularly due to the Blood Brain Barrier (BBB). The company develops carriers, specifically nanobodies (Single Domain Antibodies), that utilize the BBB's own transfer mechanisms to shuttle various drug classes, including biologics and RNA drugs, into the brain. This technology aims to improve the treatment of brain conditions by enabling therapeutic molecules to reach their target effectively, serving the pharmaceutical and life sciences industries.

Company Intelligence Q&A

What is NucleoTech's primary focus?

NucleoTech is focused on developing effective drug delivery methods to the brain, specifically addressing the challenge posed by the Blood Brain Barrier (BBB).

What technology does NucleoTech utilize for drug delivery?

NucleoTech utilizes nanobodies, also known as Single Domain Antibodies, as carrier molecules. These nanobodies leverage the BBB's natural Receptor-Mediated Transcytosis process to transport therapeutic molecules into the brain.

What types of drugs can NucleoTech's technology deliver?

NucleoTech's carriers are designed to deliver a variety of drug classes across the BBB, including biologics and RNA drugs.

When was NucleoTech founded?

NucleoTech was founded in January 2023.

Where are NucleoTech's main operations located?

NucleoTech has an address in Rehovot, Israel, and an office in Englewood, New Jersey, USA.